Quality versus quantity of life with cabozantinib and sunitinib in advanced kidney cancer

Cabozantinib and sunitinib are both drugs that block the development of blood vessels to supply the tumour and are called vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). These drugs are used to treat patients with advanced kidney cancer. Clinical trials have shown that cabozantinib is better at extending survival than sunitinib, giving patients […]

read more

Biomarkers for avelumab plus axitinib in advanced kidney cancer

The discovery of a reliable biomarker for how patients with advanced renal cell carcinoma (RCC) will respond to treatment has been very difficult to find. In this study, baseline samples from RCC tumours from patients in the phase III JAVELIN Renal 101 trial were analysed. The study showed that neither the presences of a biomarker […]

read more

First-line treatment of kidney cancer

These two videos with Dr Eric Jonasch from MD Anderson Cancer Center and Dr Elizabeth Plimack from Fox Chase Cancer Centre, both in the USA, explain how clinicians choose between the first-line treatments that are available for the treatment of renal cell carcinoma (RCC) and the long term control of the disease. Watch the video […]

read more

Safety and efficacy of apatinib for metastatic kidney cancer

A recent study coming out of China has identified a new oral tyrosine kinase inhibitor (TKI) with promising safety and efficacy for metastatic renal cell carcinoma (RCC). Anti-angiogenic treatments, such as the TKIs sunitinib, pazopanib and axitinib, play an important role in the treatment of metastatic RCC. A new TKI called apatinib targets the vascular […]

read more

Treatment of brain metastases for kidney cancer patients

Brain metastases in patients with renal cell carcinoma (RCC) is actually fairly uncommon, occurring in around 8% to 10% of all patients with metastatic RCC. Unfortunately, RCC brain metastases have been poorly studied and have a poor outcome, often with a median overall survival as low as 3 months in people with multiple brain metastases. […]

read more

First-line therapy for metastatic kidney cancer: Is two better than one?

An educational symposium was held from 8-10 August as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting. In his presentation, Dr Primo Lara from UC Davis Comprehensive Cancer Center in California discussed the first-line treatment of metastatic renal cell carcinoma (RCC), specifically whether combination therapy is better than single therapy (monotherapy). Dr […]

read more

What’s next after immunotherapy fails for advanced kidney cancer?

An educational symposium was held from 8-10 August as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting. In his presentation, Dr Toni Choueiri from Dana-Farber Cancer Institute and Harvard Medical School in Cambridge, USA, discussed treatment for patients with metastatic renal cell carcinoma (RCC) who have previously been treated with immunotherapy. Currently, […]

read more

Comparison of first-line immunotherapy combinations for metastatic kidney cancer

This meta-analysis of first-line immunotherapy trials was published in the journal Cancers last month. The analysis compares the three active first-line treatment combinations for metastatic renal cell carcinoma (RCC) and provides guidance in the selection of treatment for previously untreated patients. Three combination treatments were compared; pembrolizumab plus axitinib, avelumab plus axitinib and nivolumab plus […]

read more

Re-treatment with immune checkpoint inhibitors in kidney cancer patients

Immune checkpoint inhibitor combinations for the treatment of patients with metastatic renal cell carcinoma (RCC) have shown considerable promise. However, disease progression is inevitable for most patients. A recent review article published in Nature Reviews Clinical Oncology summarises the results of re-treatment with immune checkpoint inhibitors. Two retrospective studies investigated the safety and efficacy of […]

read more

Combination immunotherapy plus VEGFR inhibitor for favourable risk and elderly kidney cancer patients

A study published in Clinical Genitourinary Cancer this month looks at treating patients with favourable risk metastatic renal cell carcinoma (RCC) and elderly patients with a combination of immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors and VEGFR inhibitors are the most commonly used medications for […]

read more
Showing 21 to 30 of 67 results
  TOP